ZLAB - argenx slips as autoimmune disorder therapy fails in pivotal trial
2023-11-28 06:45:51 ET
More on Argenx, Halozyme, etc.
- argenx Q3: Navigating The Highs And Hurdles Of A Market Odyssey (Rating Upgrade)
- Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
- Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
- Argenx Vyvgart injectable granted EU nod for myasthenia gravis
- Halozyme, Acumen enter collaboration for Alzheimer's drug candidate
For further details see:
argenx slips as autoimmune disorder therapy fails in pivotal trial